STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2026

Mar 17, 2026

==> picture [123 x 39] intentionally omitted <==

March 17, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Symbol: STAR

Dear Madam/ Sirs,

Sub: Press Release

Please find enclosed Press Release issued by the Company titled:

“Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz”.

This is for your information and records.

Thanks & Regards, For Strides Pharma Science Limited,

MANJULA Digitally signed by MANJULA RAMAMURTHY RAMAMURTHY Date: 2026.03.17 17:58:28 +05'30'

Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No. A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Tel: +91 80 6784 0000 Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199

Press Release 17[th] March 2026

==> picture [86 x 29] intentionally omitted <==

Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz

• Existing business combined with the Sandoz portfolio is expected to position Strides as one of the top five pharmaceutical players in the Sub-Saharan Africa (SSA) region by sales, and among the top two in the represented market.

• The transaction more than doubles Strides' presence in the region

Bangalore, India, 17[th] March 2026 - Strides Pharma Science Limited (Strides) today announced ‑ that its step down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with Sandoz AG, Switzerland and its group entities (collectively referred ‑ to as “Sandoz”) for the acquisition and in licensing of a portfolio of branded generic products across Sub‑Saharan Africa (SSA).

The agreement spans four key markets—Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes ‑ multiple brands across anti infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding US$1 million, reflecting their established brand equity and market demand.

The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. To ensure the uninterrupted availability of these critical brands, Strides will also enter into a Manufacturing and Supply Agreement with Sandoz for their continued production and supply.

With the combined strength of Strides’ existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the representable market.

‑ The combination of Strides’ established operations and the high quality branded portfolio from Sandoz is expected to generate strong strategic synergies for the business. The expanded portfolio will enhance Strides’ market reach across key SSA markets, aligned with our long‑term growth strategy in Africa. The strong brand equity of Sandoz’s products is expected to strengthen Strides’ therapeutic leadership and improve credibility with prescribers. The ‑ transaction also unlocks meaningful cross selling opportunities as Strides gains access to new therapeutics and can leverage the combined portfolios across a broader network of doctors and pharmacies. Additionally, the acquisition opens new commercial channels through deeper access to prescriber bases, pharmacies, clinics, and healthcare institutions where Sandoz products already have strong presence. These synergies, combined with operational efficiencies from a strengthened commercial and supply chain platform, are expected to drive superior market coverage and long‑term value creation.

The initial consideration for the transaction is US$ 12 million, payable at closing and is expected ‑ to be funded through internal accruals. The transaction is expected to be EPS accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage.

The transaction is expected to close by the end of Q2 FY27 (Quarter Ending 30[th] September 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.

Strides Pharma Science Ltd.

1

Press Release 17[th] March 2026

==> picture [86 x 29] intentionally omitted <==

Commenting on the milestone, Aditya Kumar, Executive Director, Business Development,

said, “This acquisition represents a significant milestone for our ‘in Africa for Africa’ strategy. Africa is one of the fastest-growing geographies for us, and this transaction more than doubles our presence in the region, giving us the size and scale to accelerate our momentum, deepen market penetration, and further consolidate our leadership across key therapeutic areas. This ‑ ‑ investment is aligned with our long term strategy, under which Ex US markets are expected to evolve to mirror the scale of our US business within a couple of years. The combined portfolio strengthens our market position by enhancing our overall visibility in retail pharmacy and substantially increasing the depth and breadth of our offerings across the hospital network. We look forward to delivering enhanced value to patients and healthcare ecosystems across Sub‑Saharan Africa.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Investor Relations Vikesh Kumar: Group CFO investor-relations@strides.com Saurabh Ambaselkar: +91 99609 31220 saurabh.ambaselkar@strides.com Strides Pharma Science Limited Corp. Office: Strides House, Bannerghatta Road,Bengaluru – 560076	Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 89044 28907 Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com

2

Strides Pharma Science Ltd.